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Chronic graft-versus-host disease (GVHD) remains a major late complication of allogeneic bone marrow
transplantation (BMT). In a previous study, impaired thymic negative selection of the recipients permitted the
emergence of pathogenic T cells that cause chronic GVHD using MHC class II-deﬁcient (H2-Ab1 KO) B6 into
C3H model and CD4þ T cells isolated from chronic GVHD mice caused chronic GVHD when administered into
the secondary recipients. In this study, we evaluated the kinetics of regulatory T cell (Treg) reconstitution in
wild type B6 into C3H model. After myeloablative conditioning, host Tregs disappeared rapidly, followed by
expansion of Tregs derived from the donor splenic T cell inoculum. However, the donor splenic T cellederived
Treg pool contracted gradually and was almost completely replaced by newly generated donor bone marrow
(BM)-derived Tregs in the late post-transplantation period. Next, we compared the effects of cyclosporine
(CSA) and mammalian target of rapamycin (mTOR) inhibitors on Treg reconstitution. Administration of CSA
signiﬁcantly impaired Treg reconstitution in the spleen and thymus. In contrast, BM-derived Treg reconsti-
tution was not impaired in mTOR inhibitor-treated mice. Histopathological examination indicated that mice
treated with CSA, but not mTOR inhibitors, showed pathogenic features of chronic GVHD on day 120. Mice
treated with CSA until day 60, but not mTOR inhibitors, developed severe chronic GVHD followed by adoptive
transfer of the pathogenic CD4þ T cells isolated from H2-Ab1 KO into C3H model. These ﬁndings indicated
that long-term use of CSA impairs reconstitution of BM-derived Tregs and increases the liability to chronic
GVHD. The choice of immunosuppression, such as calcineurin inhibitor-free GVHD prophylaxis with mTOR
inhibitor, may have important implications for the control of chronic GVHD after BMT.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Chronic graft-versus-host disease (GVHD) is the most
serious late complication after allogeneic hematopoietic
stem cell transplantation, but the pathophysiology and
treatment strategy of chronic GVHD remain poorly deﬁned
[1-3]. GVHD prophylaxis using calcineurin inhibitors, such as
cyclosporine (CSA) and tacrolimus, reduces the expansion of
effector T cells by blocking interleukin (IL)-2 and prevents
acute GVHD, but fails to reduce chronic GVHD [4,5].
Administration of CSA for up to 24 months, longer than the
standard 6 months of CSA, also did not decrease the risk of
chronic GVHD [6]. Several studies have indicated that the
efﬁcacy and safety of mammalian target of rapamycindgments on page 190.
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13.11.018(mTOR) inhibitor, rapamycin (RAPA), in refractory chronic
GVHD patients [7-10]. However, a recent randomized trial
showed that the combination of RAPA and tacrolimus as
GVHD prophylaxis failed to reduce chronic GVHD compared
with tacrolimus and methotrexate [11].
CD4þCD25þFoxp3þ regulatory T cells (Tregs) have been
shown to play an important role in the establishment of
tolerance between recipient tissues and donor-derived im-
munity. A series of animal studies indicated that Tregs in the
inoculum can prevent acute GVHD when injected together
with donor T cells [12-14]. Based on the role of Tregs in the
prevention of GVHD and on their dependence on IL-2, there is
considerable concern regarding the impact of blocking IL-2
signaling or IL-2 production by the immunosuppressive
agents used for prophylaxis of GVHD. Zeiser et al. reported
that Tregs showed relative resistance to RAPA as a result of
reduced usage of the mTOR pathway and functional phos-
phatase and tensin homolog, a negative regulator of the
phosphatidyl-inositol 3-kinase/Akt/mTOR pathway in TregsTransplantation.
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Figure 1. Regulatory T cell reconstitution after allogeneic BMT. Lethally irradiated C3H (H-2k) recipient mice received 10  106 T celledepleted bone marrow (TCD-
BM) cells from B6.Ly-5a (H-2b,CD45.1) mice with/without 1 to 2  106 spleen cells from B6 (H-2b,CD45.2) mice. The syngeneic group received transplantation from
C3H mice. (A) Survival: the recipients of allogeneic BM plus 1  106 spleen cells (BM plus Sp cells) showed a survival rate of 60% by day 120. Open circle, syngeneic;
closed circle, TCD-BM cells only; triangle, -with 1  106 spleen cells; square, -with 2  106 spleen cells. (B) Origin of CD4þFoxp3þ Treg in the spleen on day 21 post
transplantation: CD45.2þ splenic T cellederived (white bars) and CD45.2e BMederived (black bars) are shown. (C) The absolute numbers of Treg in the recipients of
BM plus Sp cells (triangles) and TCD-BM (closed circles) are shown. Each group consisted of 7 to 25 mice. The means (SE) of each group are shown. Data are from a
representative of at least 3 independent experiments. *P < .05; **P < .01.
H. Sugiyama et al. / Biol Blood Marrow Transplant 20 (2014) 183e191184compared with conventional T cells [15]. In contrast to CSA,
RAPA allowed expansion of adoptively transferred Treg cells
and led to reduction of alloreactive T cell expansion when
animals received Treg treatment in combination with RAPA.
They also showed that a combination of RAPA plus IL-2
increased both expansion of donor natural Tregs and con-
version of induced Tregs from donor conventional T cells, and
suppressed acute GVHD [16]. These animal data suggest that
RAPA and CSA have differential effects on peripheral Tregs
after bone marrow transplantation (BMT).
IL-2 signaling is pivotal for Treg homeostasis in the pe-
riphery and is also essential for naturally occurring Treg
development in the thymus [17-19]. T cell repopulation after
BMT is composed of 2 subsets: T cells derived from the donor
splenic T cell inoculum and newly arising T cells from bone
marrow (BM) inoculum. It has been shown that Tregs from
the former pathway play an important role in acute GVHD,
whereas, no previous study evaluated whether use of CSA for
an extended period affects donor BM-derived Treg genera-
tion. We hypothesized that BM-derived Tregs comprise the
long-term peripheral Treg pool and that CSA, but not mTOR
inhibitors, causes impaired BM-derived Treg reconstitution,
which has a negative effect on chronic GVHD. In the present
study, we therefore evaluated effects of different immuno-
suppressants on 2 distinct Treg expansion reconstitution
pathways and on the development of chronic GVHD.
MATERIALS AND METHODS
Mice
Female C57BL/6 (B6: H-2b, CD45.2þ) and C3H/HeN (C3H: H-2k)micewere
purchased from Charles River Japan (Yokohama, Japan) or from the Okayama
University mouse colony (Okayama, Japan). B6-Ly5a (H-2b, CD45.1þ) and
C3.SW (H-2b, CD45.2þ) mice were purchased from Jackson Laboratory (Bar
Harbor, ME). B6-background MHC class II-deﬁcient H2-Ab1/mice (B6.129-
H2-Ab1tm1Gru N12) were from Taconic Farms (Germantown, NY) [20]. Mice
between 8 and 18 weeks of age were maintained under speciﬁc pathogen-
free conditions and received normal chow and hyperchlorinated drinkingwater after transplantation. All experiments involving animals were
approved by the Institutional Animal Care and Research Advisory Committee,
Okayama University Advanced Science Research Center.
BMT
Mice underwent transplantation according to the standard protocol
described previously [21,22]. Brieﬂy, recipient mice received 2 split doses of
either 500 cGy (allogeneic C3H and C3.SW recipients) or 650 cGy (syngeneic
B6 recipients) total-body irradiation (TBI) 3 to 4 hours apart. Recipients were
injected with 10 106 T celledepleted bonemarrow (TCD-BM) cells plus 1 or
2106 whole spleen cells from B6 donors. [H2-Ab1//C3H] chimeraswere
produced by reconstituting lethally irradiated C3Hmicewith 5106 TCD-BM
cells from H2-Ab1/mice, as described previously [23]. T cell depletion was
performed using anti-CD90emicrobeads and an AutoMACS system (Miltenyi
Biotec, Auburn, CA) according to the manufacturer’s instructions. Donor cells
were injected intravenously into the recipients on day 0.
Immunosuppressive Treatment
RAPAwas purchased from Toronto Research Chemicals Inc. (North York,
ON, Canada). Everolimus (RAD) and CSA were synthesized and provided by
Novartis Pharma AG (Basel, Switzerland). Everolimus emulsion was dis-
solved in distilled water at a concentration of 625 mg/mL and administered
to recipients by oral gavage at a dose of 5mg/kg. RAPA and CSAwere given as
suspensions in carboxymethylcellulose sodium salt: CMC (C5013; Sigma-
Aldrich, St. Louis, MO) at a ﬁnal concentration of .2% CMC. RAPA and CSA
were administered to recipients by peritoneal injection at doses of .5 and
20 mg/kg, respectively [15,24]. Immunosuppressive treatments were per-
formed once daily, starting on day 0 and continuing until death or end of the
observation period (day 110 to 125).
Adoptive Transfer
Splenocytes were isolated from [H2-Ab1//C3H] chimeras 6 to
11 weeks after TCD-BMT. CD4þ T cells were negatively selected from sple-
nocytes by depletion of CD8þ, DX5þ, CD11bþ, Ter-119þ, and B220þ cells
using the AutoMACS system, as described previously [23]. A total of 2  107
CD4þ T cells per mouse were injected intravenously into recipients after
immunosuppressive therapy for 70 days after BMT.
Assessment of GVHD
After BMT, survival was monitored daily, and weight changes were
assessed twice per week. The degree of clinically acute GVHD was assessed
twice per week using a scoring system that sums changes in 5 clinical
Figure 2. Donor BMederived progenitors comprise the long-term peripheral Treg pool. Lethally irradiated C3H recipients underwent transplantation as in Figure 1:
(B6/ C3H). The rates of CD45.2þ spleen cellederived (broken lines) and CD45.2e BMederived (solid lines) Treg in CD4þFoxp3þ Treg are shown. Spleen (A) and
mesenteric lymph nodes (MLN) (B) were isolated from (B6/ C3H) mice at various time points after BMT and cells were analyzed by ﬂuorescent activated cell sorter.
(C) Lethally irradiated C3.SW (H-2b) recipients underwent transplantation from B6 (H-2b) donors. The rates of CD45.2þ splenic T cellederived (broken lines) and
CD45.2e BMederived (solid lines) Treg in CD4þFoxp3þ Treg in the spleen are shown. Each group consisted of 20 to 23 mice. The means (SE) of each group are
shown. Data are from a representative of at least 2 independent experiments. (D) CD25þCD4þ Treg were puriﬁed from the spleens of (B6/ C3H) mice (on day 120) or
naïve B6 (WT). B6 CD4þCD25e T cells (Tcon) together with various numbers of Treg were cultured with irradiated C3H CD11cþ DC as stimulators for 72 hours.
Proliferative activities were determined by monitoring 3H-thymidine uptake.
H. Sugiyama et al. / Biol Blood Marrow Transplant 20 (2014) 183e191 185parameters: weight loss, posture, activity, fur texture, and skin integrity
(maximum index, 10), as described previously [22]. Shaved skin from the
interscapular region (approximately 2 cm2), liver, and salivary gland speci-
mens of recipients were ﬁxed in 10% formalin, embedded in parafﬁn,
sectioned, mounted on slides, and stained with hematoxylin and eosin. Skin
slides were scored on the basis of dermal ﬁbrosis, fat loss, inﬂammation,
epidermal interface changes, and follicular drop out (0 to 2 for each category;
the maximum score was 10) [21]. Liver slides were scored based on bile duct
injury and inﬂammation (0 to 4 for each category), and the maximum score
was 8 [25]. Salivary gland slides were scored based on atrophy and inﬂam-
mation (0 to 3 for each category), and the maximum score was 6. All slides
were scored by pathologists (T.K. and T.T.) blind to experimental group.Immunohistochemistry
Immunohistochemical staining for Foxp3 and CD3 was performed using
the high polymer (HISTOFINE simple stain, NICHIREI, Tokyo, Japan) method.
Anti-Foxp3 (eBioscience) and anti-CD3 (Abcam, Cambridge, MA) were used
to identify Tregs and effector T cells, respectively.Flow Cytometry
The mAbs used were unconjugated anti-CD16/32 (2.4G2); FITC-, PE-,
PerCP-, or APC-conjugated anti-mouse CD4, CD25, CD45.1, CD45.2, H-2b, H-
2d (BD Pharmingen, San Diego, CA); and Foxp3 (eBioscience, San Diego, CA),
as described previously [26]. A Foxp3 staining kit (eBioscience) was used for
intracellular staining. Cells were analyzed on a FACSAria ﬂow cytometer
with FACSDiva software (BD Immunocytometry Systems, San Diego, CA).Mixed Leukocyte Reaction
CD4þCD25e T cells, CD4þCD25þ T cells, and CD11cþ DC were magneti-
cally separated by AutoMACS using microbeads from a CD4þCD25þ regula-
tory Tcell isolation kit and CD11cmicrobeads. CD4þCD25e Tcells (5104 per
well) together with various numbers of CD25þCD4þ T cells (0 to 5  104 per
well) were cultured with irradiated (30 Gy) CD11cþ DC as stimulators for
72 hours in 96-well round-bottomed plates. Cells were pulsed with 3H-
thymidine (1 mCi [.037MBq] perwell) for a further 16 hours [27]. Proliferation
was determined using Topcount NXT (Packard Instruments, Meriden, CT).
Statistics
Data are given as means  SEM. The survival curves were plotted using
Kaplan-Meier estimates. Group comparisons of pathology scores were per-
formed using the Mann-Whitney U test. Comparative analysis of cell ratios
was performed by the unpaired 2-tailed Student t-test or Welch’s t-test. In
all analyses, P < .05 was taken to indicate statistical signiﬁcance.
RESULTS
Kinetics of Treg Reconstitution after Allogeneic BMT
We ﬁrst examined whether Tregs intermixed in the graft
persist in the host for long periods post BMT using the MHC-
mismatched model of BMT. Lethally irradiated C3H (H-2k)
recipient mice received 10  106 TCD-BM cells from B6.Ly-5a
(H-2b,CD45.1) mice with/without 1 to 2  106 spleen cells
from B6 (H-2b,CD45.2) mice. All of the recipients of allogeneic
C3H TCD-BM cells from B6mice and syngeneic mice survived
and were resistant to induction of GVHD. Although 100% of
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Figure 3. Effects of CSA and mTOR inhibitors on the Treg compartment. Lethally irradiated C3H recipients underwent transplantation from B6 donor mice as shown
in Figure 1 and received i.p. injections of CSA (closed squares), mTOR inhibitor (rapamycin, RAPA; open triangles), or vehicle control (open squares) daily from day 0 to
110. The rates of CD45.2þ splenic T cellederived (broken lines) and CD45.2e BMederived (solid lines) Treg in CD4þFoxp3þ Treg are shown. Spleen (A) and mesenteric
lymph nodes (MLN) (B) were isolated from (B6/ C3H) mice at various time points after BMT and cells were analyzed by ﬂuorescent activated cell sorter. Each group
consisted of 16 to 23 mice. The means (SE) of each group are shown. Data are from a representative of at least 2 independent experiments.
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cells died by day 35 with clinical and histopathological signs
of severe GVHD, the recipients of allogeneic BM plus 1  106
spleen cells (BM plus Sp cells) showed mild clinical signs of
GVHD and 60% survived by day 120 (Figure 1A); the following
experiment was performed in this setting. Flow cytometric
analysis of donor cell chimerism in the spleen 3 weeks after
allogeneic BMT showed that 98.8% 0.7% of spleen cells were
derived from the donor in mice, thus conﬁrming complete
donor cell engraftment. Host Tregs, as determined by
CD4þFoxp3þH-2kþ, were not detected in the spleen on day 21
post transplantation (data not shown). On day 21 post
transplantation, the majority of CD4þFoxp3þ Tregs were
derived from CD45.2þ splenic T cells (83.4%  2.2%), sug-
gesting that splenic T cellederived Tregs underwent ho-
meostatic and/or alloantigen-driven expansion (Figure 1B)
and the absolute number of Tregs in the spleens of the re-
cipients of BM plus Sp cells was signiﬁcantly higher than in
TCD-BM recipients. From day 21 onward, due to GVHD-
induced lymphopenia, the absolute number of Tregs in theFigure 4. CSA, but not mTOR, inhibitors hampered reconstitution of BM-derived Treg
(rapamycin, RAPA; gray bars), or vehicle control (white bars) daily from day 0 to 110
shown. Each group consisted of 19 to 26 mice. The means (SE) of each group are s
*P < .05; **P < .01.spleens of recipients of BM plus Sp cells was lower than in
TCD-BM recipients (Figure 1C). The rate of CD45.2þ splenic T
cellederived Tregs in CD4þFoxp3þ Treg decreased gradually
and most CD4þFoxp3þ Treg were CD45.1þ BM-derived
(93.2%) on day 125 post transplantation (Figure 2A). The
rate of CD45.1þ BM-derived Tregs in the mesenteric lymph
nodes (MLN) was also increased and became dominant in the
late post-transplantation period (Figure 2B). To exclude
strain-dependent artifacts, we next evaluated the kinetics of
Treg reconstitution in the B6 (H-2b) into C3.SW (H-2b) MHC-
compatible, multiple minor histocompatibility antigen
(miHA)-incompatible model of SCT. The kinetics of Treg
reconstitution in the spleen was similar and most
CD4þFoxp3þ Tregs were derived from CD45.1þ BM (97%) on
day 90 post transplantation (Figure 2C). These ﬁndings indi-
cated that the peripheral Treg pool was restored ﬁrst by
expanded splenic T cellederived mature Treg and then by
new Tregs generated from donor BM-derived progenitors.
Next, to examine the function of newly arising Tregs, puriﬁed
CD4þCD25þ T cells on day 120 post transplantation were. (B6/ C3H) mice received i.p. injections of CSA (black bars), mTOR inhibitor
. The absolute numbers of Treg in the spleen (A), MLN (B), and thymus (C) are
hown. Data are from a representative of at least 2 independent experiments.
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ing syngeneic CD4þCD25e B6 T cells. Their suppressive ac-
tivity was virtually indistinguishable from that of Tregs
obtained from normal B6 mice (Figure 2D). Taken together,
Tregs generated from donor BM-derived progenitors
comprise the long-term peripheral Treg pool and exhibit
immunosuppressive activity.CSA, but Not mTORinhibitors, Hampered Reconstitution
of BM-derived Treg
Coenen et al. reported that 28 days of CSA administration
hampered Treg homeostasis in normal mice [28]. We
examined whether the use of CSA for an extended period
affected the long-term peripheral Treg pool after BMT. C3H
recipient mice underwent transplantation from B6 donor
mice (as shown in Figure 1) and received i.p. injection of CSA,
mTOR inhibitor (rapamycin; RAPA), or vehicle control daily
from day 0. We analyzed the effects of CSA and RAPA on the
Treg compartment at 21, 35, 56, and 110 days post hemato-
poietic cell transplantation. Mice treated with CSA or RAPA
showed the same Treg reconstitution pattern as those
treatedwith vehicle solution. On day 21 post transplantation,
the majority of CD4þFoxp3þ Tregs in the spleen were
CD45.2þ splenic T cellederived cells but the Treg compart-
ments were dominated by BM-derived cells on days 56 and
110 post transplantation in all 3 groups (Figure 3A). In the
MLN, these 3 groups also showed similar Treg reconstitution
kinetics (Figure 3B). There were no differences in the abso-
lute numbers of Treg among the 3 groups on day 21. From
day 21 onward, however, the absolute numbers of Tregs in
the CSA-treated mice were lower than those in control mice
both in the spleen (day 56: 1.3  .4 versus 4.6  .8  105,
P < .01; day 110: 10.4  1.4 versus 16.7  2.4  105, P < .05)
(Figure 4A) and in the MLN (day 56: 1.3  .5 versus
7.4  1.6  104, P < .03; day 110: 2.9  1.0 versus
4.9  1.9  105, P ¼ .46) (Figure 4B). Especially in the thymus,
mice treated with CSA showed a marked reduction in theFigure 5. CSA, but not mTOR, inhibitors increased the likelihood of chronic GVHD. (A)
(on day 120) from (B6/ C3H) mice given CSA, mTOR inhibitor (RAPA, RAD), or vehi
follicular dropout, and dermal thickness (b); ﬁbrosis in the portal area and peripheral
tissue in the salivary glands (j) were observed (original magniﬁcation:  100) Patholog
means  SE. Data are from a representative of at least 2 independent experiments. *absolute numbers of Tregs compared with those treatedwith
vehicle control (day 110: 4.6  1.8 versus 25.7  5.0  104,
P < .01) (Figure 4C). In contrast to mice treated with CSA,
mice treated with RAPA showed no reduction in the absolute
numbers of Tregs and no differences compared with control
mice in the spleen or MLN at any time point post trans-
plantation (Figure 4A,B). The absolute numbers of newly
arising Tregs in the thymus were also not reduced in mice
treated with RAPA (Figure 4C). We next examined the effects
of another mTOR inhibitor, everolimus (RAD), which exhibits
greater polarity than RAPA and has been approved in Europe
for use as an immunosuppressant for prevention of cardiac
and renal allograft rejection. Reconstitution of newly arising
Tregs in the thymus was not impaired in mice treated with
RAD, and there were no differences in the absolute numbers
of spleen Tregs compared with control mice on day 110
(spleen: 15.4  2.5 versus 16.6  2.4  105, P ¼ .73, Supple-
mental Figure 1A; thymus: 17.4 3.2 versus 25.7 5.0 104,
P ¼ .26, Supplemental Figure 1B). These ﬁndings suggested
that CSA, but not mTOR inhibitors, hampered the long-term
reconstitution of BM-derived Tregs.CSA, but Not mTOR Inhibitors, Increased Liability to
Chronic GVHD
Recent studies revealed the association of reduced Treg
frequency in patients with chronic GVHD. In the present
study, we examined histopathological change in CSA-treated
mice where reconstitution of BM-derived Tregs was
impaired. The skin of CSA-treated mice showed pathogenic
features of chronic GVHD (Figure 5A), and pathogenic scores
revealed signiﬁcantly exacerbated chronic GVHD pathology
compared with those treated with vehicle control (5.5  .8
versus 1.6 .3, P< .01) (Figure 5B). A dry mouth is one of the
distinctive features of chronic GVHD. Lymphocytic inﬂam-
mation, ﬁbrosis, and atrophy of acinar tissue were observed
in the salivary glands of CSA-treated mice (Figure 5A) and
pathological scores were signiﬁcantly higher in CSA-treatedHistological ﬁndings of the skin (a to d), liver (e to h), and salivary glands (i to l)
cle control. Sclerodermatous skin changes, such as epidermal atrophy, fat loss,
mononuclear cells inﬁltrates in the liver (f); and ﬁbrosis and atrophy of acinar
ical scores of skin (B), salivary gland (C) and liver (D). The data are expressed as
P < .05; **P < .01.
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(Figure 5C). CSA-treated mice showed bile duct injury and
ﬁbrosis in the portal area and peripheral mononuclear cell
inﬁltration in the liver and pathological scores of the liver
also tended to be worse in CSA-treated mice, as compared
with those treated with vehicle control, although it was not
statistically signiﬁcant (Figure 5D). In contrast to mice
treated with CSA, mice treated with RAPA showed no
pathogenic features of chronic GVHD and there were no
differences in pathogenic skin and salivary gland scores, as
compared with control mice (skin: .75  .4 versus 1.6  .3,
P ¼ .18, Figure 5B; salivary gland: 1.25  .2 versus1.78  .1,
P¼ .08, Figure 5C). Immunohistochemical staining for Foxp3
and CD3 revealed that CD3þ T cells inﬁltrated in the skin
tissue of all 3 groups, and RAD-treated mice showed
abundant inﬁltration by CD3þ T cells and Foxp3þ cells
(Figure 6A). In contrast to RAD, Foxp3þ cells were scarcely
found in skin tissue of CSA-treated mice. The ratio of Foxp3
Tregs per 100 CD3þ lymphocytes in the skin tissue of
CSA-treated mice was signiﬁcantly lower than those in
RAD-treated mice (3.23  .4 versus 19.5  4.4, P < .05). CSA-
treated mice tended to show poorer survival, as compared
with those treated with mTOR inhibitors or vehicle control
(CSA 27.6% versus control 54.2%, RAD 57.1%, RAPA 61.5%,
P ¼ .28, Supplemental data Figure 2). These ﬁndings sug-
gested that CSA, but not mTOR inhibitors, hampered the
reconstitution of BM-derived Treg and increased liability to
chronic GVHD.Figure 6. CSA, but not mTOR, reduces Treg inﬁltration in skin tissue. (A) Lethally irrad
in Figure 1 and received vehicle control (a, d), CSA (b, e), or mTOR inhibitor (RAD; c, f
anti-Foxp3 (a to c) and anti-CD3 (d to f) antibodies on day 120. Arrows indicate Fox
number of CD3 and Foxp3 cells was counted in all the high-power ﬁelds. Results a
independent experiments. (n ¼ 3 to 4 per group). *P < .05.We next tested liability to chronic GVHD in CSA-treated
mice using adoptive transfer experiments. Previously,
Sakoda et al. demonstrated that impaired thymic negative
selection of the recipients permitted the emergence of
pathogenic T cells that cause chronic GVHD (Figure 7A) [23].
Lethally irradiated C3H recipients were reconstituted with
TCD BM from MHC class II-deﬁcient (H2-Ab1/) B6 mice
([H2-Ab1//C3H]). These mice developed disease condi-
tions that showed all of the clinical and histopathological
features of human chronic GVHD. CD4þ T cells isolated from
chronic GVHD mice ([H2-Ab1//C3H] CD4þ T cells) cause
chronic GVHD when B6 antigens are provided by hemato-
poietic cells in the absence of B6 antigen expression on
target epithelium ([B6/C3H] chimeras) [23]. In the current
study, C3H mice underwent transplantation from B6 donors
as shown in Figure 1 and were orally administered CSA,
RAPA, or vehicle solution until 60 days post BMT, when none
of the recipients showed signiﬁcant signs of chronic GVHD.
To test liability to chronic GVHD, these C3H-recipient mice
with B6-derived antigen presenting cells received adoptive
transfer of [H2-Ab1//C3H] CD4þ T cells (Figure 7B). As
shown in Figure 7C and D, adoptive transfer of pathogenic
CD4þ T cells caused severe weight loss (CSA 81.1  4.1%
versus control 94.5  2.1%, P < .05; and CSA 81.1  4.1%
versus RAPA 98.9  1.5%, P < .01) and chronic GVHD in CSA-
treated mice, with a mortality rate of 83%. RAPA-treated
mice and controls showed resistance to induction of
chronic GVHD by transfer of pathogenic CD4þ T cells; theiated C3H recipients underwent transplantation from B6 donor mice as shown
), daily from day 0 to 120. Immunohistochemical staining was performed using
p3 positive cells. (B) The ratio of Foxp3 Tregs per 100 CD3þ lymphocytes. The
re expressed as mean  SD. Pictures and data are from a representative of 2
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pathogenic CD4+ T cells
B6 classII-/- → C3H
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Figure 7. Adoptive transfer of pathogenic CD4þ T cells caused severe chronic GVHD. (A) Lethally irradiated C3H recipients were reconstituted with TCD BM fromMHC
class II-deﬁcient (H2-Ab1/) B6 mice. These mice developed chronic GVHD and CD4þ T cells isolated from chronic GVHD mice ([H2-Ab1//C3H] CD4þ T cells)
were primarily donor reactive. These pathogenic CD4þ T cells cause chronic GVHD when B6 antigens are provided by hematopoietic cells in the absence of B6 antigen
expression on target epithelium ([B6/C3H] chimeras). (B) C3H recipient mice underwent transplantation from B6 donors as shown in Figure 1 and received CSA,
RAPA, or vehicle solution until 60 days post BMT. These C3H recipient mice received adoptive transfer of [H2-Ab1//C3H] CD4þ T cells. Body weight change is
shown in (C) and overall survival is shown in (D). Data from 3 similar experiments are combined (n ¼ 8 to 12 per group). The data are expressed as means  SE.
*P < .05; **P < .01.
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Taken together, these data demonstrated that CSA, but not
mTOR inhibitors, increased liability to chronic GVHD.
DISCUSSION
Patients with chronic GVHD have a lower frequency of
Tregs when compared with patients without chronic GVHD
[29-32]. Experimental BMT demonstrated that Tregs in the
inoculum can prevent acute GVHD when injected together
with donor T cells [12-14]; however, it is not known whether
Tregs in the grafts persist into the late post-transplantation
period and play a role in preventing chronic GVHD. Mas-
tuoka et al. prospectively monitored CD4þ T cell subsets and
showed that thymic generation of naïve Treg was markedly
impaired and Treg levels subsequently declined in patients
with prolonged CD4þ lymphopenia [32]. This resulted in a
relative Treg deﬁciency, which was associated with a high
incidence of extensive chronic GVHD. In the present study, we
monitored Treg reconstitution kinetics in the spleen, MLN,
and thymus according to 2 subsets, T cells derived from
peripheral-expanded mature T cells and newly arising T cells
from bone marrow stem cells, using 2 mouse BMT models
because this is difﬁcult to examine in a human setting. The
results indicated that host Tregs disappeared rapidly in mice
receiving allogeneic T cells early in the early post-
transplantation period, consistent with a previous report
[33]. In addition, this study showed that splenic Tcellederived
Treg initially occupy a niche in lymphopenic transplantation
recipients, suggesting that mature Treg underwent homeo-
static and/or alloantigen-driven expansion. However, the
donor splenic T cellederived Treg pool contracted gradually
and Tregs generated from donor BM-derived progenitorscomprised the long-term peripheral Treg pool. The BM-
derived Treg compartment was functionally competent, as
determined by in vitro lymphoid suppression, indicating that
these cells play a role in post-BMT immune tolerance.
Coenen et al. reported that 28 days of treatment with CSA
resulted in a reduction in thymic generation of CD4þFoxp3þ T
cells and peripheral CD25þFoxp3þ Tcells in normalmice [28].
We assessed whether CSA affects the peripheral Treg pool
after allogeneic BMT; on day 21, there were no differences in
the absolute numbers of Tregs among 3 groups, and CSA had
no impact on early Treg reconstitution. Consistent with our
observations, Setoguchi et al. reported that in contrast to the
requirement of IL-2 for physiological expansion of
CD4þCD25þ Treg cells in normal nonlymphopenic mice, ho-
meostatic proliferation in a lymphopenic environment ap-
pears to be IL-2-independent [19]. Zeiser et al. also reported
that CSA administration has only a minor impact on the
expansion of adoptively transferred CD4þCD25þ T cells on
day 7 post transplantation [34]. However, whether prolonged
use of CSA affects the long-term peripheral Treg pool has not
been reported. Our data showed that CSA, but not mTOR in-
hibitors, hampered the long-term reconstitution of BM-
derived Tregs. The numbers of Tregs in the spleen, thymus
and tissuewere signiﬁcantly reduced inmice receiving CSA in
comparison with those receiving mTOR inhibitors or PBS on
day 110. CSA blocks nuclear factor of activated T cells trans-
location into the nucleus by inhibiting calcineurin phospha-
tase activity [35]. CSA inhibits the thymic generation of Tregs
by impairment of TCR signaling and by reducing nuclear
factor of activated Tcellsedependent Foxp3 promoter activity
[36]. In contrast, rapamycin-sensitive downstream targets
of phosphatidyl-inositol 3-kinase are IL-2-independent, and
H. Sugiyama et al. / Biol Blood Marrow Transplant 20 (2014) 183e191190rapamycin affects neither the initial signal transduction upon
TCR triggering nor the thymic generation of Treg [37].
Immunosuppressive drugs have different mechanisms of
promoting immune suppression and our data revealed
different effects on the long-term peripheral Treg pool after
allogeneic BMT.
Although mouse models of chronic GVHD have provided
important insights into pathophysiology of this disease, one
factor that confounds the translation of ﬁndings in mouse
models to the human disease is that time course of devel-
opment of chronic GVHD ismore rapid inmostmousemodels
than in human. Another factor is that most patients are given
immunosuppressive therapy to prevent acute GVHD [38], and
these medications might inﬂuence the development of
chronic GVHD. In this study, histopathological examination
revealed that CSA-treated mice showed pathogenic features
of chronic GVHD, whereas those treated with mTOR in-
hibitors showed no signiﬁcant differences compared with
control mice. This is the ﬁrst report that long-term use of CSA
induces chronic GVHD in transplant-recipient mice. This may
have been due to induction of autoreactive T cells by CSA
[39,40]. Wu et al. reported that CSA contributes to chronic
GVHD in experimental models, which was ascribed to the
disruption of clonal-deletion mechanisms in the thymus,
resulting in the export of autoreactive T cells [41]. The present
study demonstrated another mechanism by which CSA
impaired Treg reconstitution. Adoptive transfer of the path-
ogenic CD4þ T cells caused severe chronic GVHD in CSA-
treated mice, whereas mTOR inhibitor-treated and control
mice showed resistance to induction of chronic GVHD. These
ﬁndings suggest that the increased liability to chronic GVHD
in CSA-treated mice might be due to limited reconstitution of
BM-derived Treg cells; further mechanistic studies will be
required to determine if this is truly causative rather than
merely an association.
Here, we assessed the differential effects of CSA and
mTOR inhibitors on the long-term peripheral Treg pool after
allogeneic BMT. Our ﬁndings indicated that, in contrast to
mTOR inhibitors, CSA compromises homeostasis in periph-
eral immune compartments and thymic generation of
CD4þCD25þFoxp3þ T cells. GVHD prophylaxis with mTOR
inhibitor and calcineurin inhibitor failed to reduce chronic
GVHD [11,42-45]. The choice of calcineurin inhibitorefree
GVHD prophylaxis with mTOR inhibitors, such as mTOR in-
hibitors plus IL-2 [16] or mTOR inhibitors plus antithymocyte
globulin [46] may have important implications for the con-
trol of chronic GVHD after BMT.ACKNOWLEDGMENTS
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